Histamine Phosphate

NDA 734, held by Lilly. Histamine Phosphate.

As of Nov 15, 2026, NDA 734 (Histamine Phosphate), held by Lilly, was first approved by FDA on Apr 25, 1939, with 1 approved supplement and 0 published complete response letters.

First approved: Apr 25, 1939
Supplements approved: 1
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 2 submissions below

Date	Submission	Status	Documents
Apr 25, 1939	Original application	Approved	None posted

Products

3 strengths and forms


Histamine PhosphateEQ 1MG BASE/ML · injectable;injection	Histamine Phosphate	Discontinued
Histamine PhosphateEQ 0.2MG BASE/ML · injectable;injection	Histamine Phosphate	Discontinued
Histamine PhosphateEQ 0.1MG BASE/ML · injectable;injection	Histamine Phosphate	Discontinued

All 2 submissions, including labeling and manufacturing supplements


Aug 13, 1980	Supplement 8Manufacturing	Approved	None posted
Apr 25, 1939	Original application	Approved	None posted

Identifiers

Application: NDA 734
Drugs@FDA: Overview at FDA
Company: Lilly

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters